MX2020008906A - Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. - Google Patents

Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.

Info

Publication number
MX2020008906A
MX2020008906A MX2020008906A MX2020008906A MX2020008906A MX 2020008906 A MX2020008906 A MX 2020008906A MX 2020008906 A MX2020008906 A MX 2020008906A MX 2020008906 A MX2020008906 A MX 2020008906A MX 2020008906 A MX2020008906 A MX 2020008906A
Authority
MX
Mexico
Prior art keywords
compounds
inducing activity
methods
ferroptosis
ferroptosis inducing
Prior art date
Application number
MX2020008906A
Other languages
English (en)
Inventor
Anjali Pandey
Chun Jiang
Athisayamani Jeyaraj Duraiswamy
Ruihong Chen
Biswajit Kalita
Original Assignee
Ferro Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferro Therapeutics Inc filed Critical Ferro Therapeutics Inc
Publication of MX2020008906A publication Critical patent/MX2020008906A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Esta presente divulgación se refiere a compuestos con actividad inductora de ferroptosis, un método para tratar a un sujeto con cáncer con los compuestos, y tratamientos de combinación con un segundo agente terapéutico.
MX2020008906A 2018-02-28 2019-02-27 Compuestos con actividad inductora de ferroptosis y métodos de uso de estos. MX2020008906A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862636614P 2018-02-28 2018-02-28
PCT/US2019/019854 WO2019168999A1 (en) 2018-02-28 2019-02-27 Compounds with ferroptosis inducing activity and methods of their use

Publications (1)

Publication Number Publication Date
MX2020008906A true MX2020008906A (es) 2021-02-26

Family

ID=65729467

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020008906A MX2020008906A (es) 2018-02-28 2019-02-27 Compuestos con actividad inductora de ferroptosis y métodos de uso de estos.
MX2023001527A MX2023001527A (es) 2018-02-28 2020-08-26 Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023001527A MX2023001527A (es) 2018-02-28 2020-08-26 Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.

Country Status (15)

Country Link
US (2) US11098040B2 (es)
EP (1) EP3759075A1 (es)
JP (1) JP7348906B2 (es)
KR (1) KR20200135961A (es)
CN (1) CN112041301A (es)
AR (2) AR114417A1 (es)
AU (1) AU2019229256A1 (es)
BR (1) BR112020017561A2 (es)
CA (1) CA3092143A1 (es)
EA (1) EA202091846A1 (es)
IL (1) IL276788A (es)
MX (2) MX2020008906A (es)
SG (1) SG11202008230PA (es)
TW (1) TW202000663A (es)
WO (1) WO2019168999A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11040964B2 (en) 2019-02-27 2021-06-22 Ferro Therapeutics, Inc. Compounds and methods of use
SG11202109035QA (en) * 2019-02-27 2021-09-29 Ferro Therapeutics Inc Compounds with ferroptosis inducing activity and methods of their use
CN110511253B (zh) * 2019-09-04 2023-10-13 上海药明康德新药开发有限公司 DNA编码化合物库构建中On-DNA四氢-β-咔啉类化合物的合成方法
CN110627786B (zh) * 2019-10-29 2020-11-24 株洲千金药业股份有限公司 一种他达拉非中间体的制备方法
WO2021127217A1 (en) 2019-12-17 2021-06-24 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
JP2023518132A (ja) * 2020-03-06 2023-04-27 ベイジン・シノタウ・バイオ－ファーマシューティカルズ・テクノロジー・カンパニー，リミテッド Ｃｔｂ００６とポナチニブとの併用の適用
WO2022042657A1 (en) * 2020-08-26 2022-03-03 Ferro Therapeutics, Inc. Compounds and methods of use
KR20220139813A (ko) * 2021-04-08 2022-10-17 서울대학교산학협력단 암 환자의 예후 예측용 바이오마커 및 이의 용도
CN113336748B (zh) * 2021-04-12 2022-03-25 北京大学 一种gpx4蛋白降解剂及其制备方法和应用、一种抗肿瘤细胞药物
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo
WO2024015637A1 (en) * 2022-07-15 2024-01-18 Ferro Therapeutics, Inc. Glutathione peroxidase 4 (gpx4) inhibitors for the treatment of cancer
WO2024039860A1 (en) * 2022-08-19 2024-02-22 Olema Pharmaceuticals, Inc. 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
AU2001268064A1 (en) * 2000-06-07 2001-12-17 Lilly Icos Llc Derivatives of 2,3,6,7,12,12a-hexahydropyrazino(1',2':1,6)pyrido(3,4-b)indole-1,4-dione
JP2004533402A (ja) * 2000-06-08 2004-11-04 リリー アイコス リミテッド ライアビリティ カンパニー Ｐｄｅｖインヒビターとしての四環系ジケトピペラジン化合物
DE60111553T2 (de) 2000-10-02 2006-04-06 Lilly Icos Llc, Wilmington Hexahydropyrazino[1'2':1,6]-pyrido[3,4-b]indole-1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
AU2001296699A1 (en) 2000-11-08 2002-05-21 Lilly Icos Llc Condensed pyrazindione derivatives as pde inhibitors
EP2324886A1 (en) * 2005-07-29 2011-05-25 Concert Pharmaceuticals Inc. Novel deuterated analogues of tadalafil
EP1914235A1 (en) 2006-10-10 2008-04-23 Universite de Lille 2 Droit et Santé Chiral tetra-hydro beta-carboline derivatives and applications thereof as antiparasitic compounds
WO2008103470A2 (en) 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Oncogenic-ras-signal dependent lethal compounds
FR2916200A1 (fr) 2007-05-18 2008-11-21 Fourtillan Snc Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique
US9169247B2 (en) 2009-11-20 2015-10-27 Southern Research Institute Tetrahydro-beta-carboline derivatives, synthesis and use thereof
US9695133B2 (en) * 2012-07-13 2017-07-04 The Trustees Of Columbia University In The City Of New York Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use
WO2015051149A1 (en) 2013-10-04 2015-04-09 The Trustees Of Columbia University In The City Of New York Sorafenib analogs and uses thereof
US9938245B2 (en) 2014-01-15 2018-04-10 The Trustees Of Columbia University In The City Of New York Carbonyl erastin analogs and their use
WO2016099452A1 (en) 2014-12-16 2016-06-23 Adt Pharmaceuticals, Inc. Ras-inhibiting indenyl acetamide compounds, compositions, and uses
US10736972B2 (en) 2015-05-29 2020-08-11 Memorial Sloan Kettering Cancer Center Methods of treatment using ultrasmall nanoparticles to induce cell death of nutrient-deprived cancer cells via ferroptosis
KR102099159B1 (ko) 2015-11-12 2020-04-10 쯔지앙 하이썬 파머슈티컬 컴퍼니, 리미티드 아크릴산 유도체, 그의 제조방법 및 의약에 있어서의 그의 사용방법
US20190008961A1 (en) * 2016-01-07 2019-01-10 The Broad Institute, Inc. Compounds and methods for increasing tumor infiltration by immune cells
US10407611B2 (en) 2016-01-08 2019-09-10 Ecolab Usa Inc. Heavy oil rheology modifiers for flow improvement during production and transportation operations
BR112018015419B1 (pt) 2016-02-05 2024-01-30 Inventisbio Llc Degradantes seletivos de receptor de estrogênio, seus usos, e composição farmacêutica
WO2018118711A1 (en) 2016-12-19 2018-06-28 The Trustees Of Columbia University In The City Of New York Small molecule ferroptosis inducers
WO2018218087A1 (en) 2017-05-24 2018-11-29 K-Gen, Inc. Methods of cancer treatment
EP4085919A3 (en) 2017-07-21 2023-02-08 Novartis AG Compositions and methods to treat cancer
WO2019106434A1 (en) 2017-12-01 2019-06-06 Collaborative Medicinal Development Pty. Ltd. Heterobicyclic aromatic derivatives for the treatment of ferroptosis-related disorders
US20200383943A1 (en) 2017-12-04 2020-12-10 Memorial Sloan Kettering Cancer Center Methods of cancer treatment via regulated ferroptosis
CN109796424A (zh) 2019-02-19 2019-05-24 四川大学 一种抑制铁死亡的小分子化合物及其制备方法与应用
SG11202109035QA (en) 2019-02-27 2021-09-29 Ferro Therapeutics Inc Compounds with ferroptosis inducing activity and methods of their use

Also Published As

Publication number Publication date
TW202000663A (zh) 2020-01-01
IL276788A (en) 2020-10-29
EA202091846A1 (ru) 2021-06-01
KR20200135961A (ko) 2020-12-04
US11098040B2 (en) 2021-08-24
BR112020017561A2 (pt) 2020-12-22
AR118205A1 (es) 2021-09-22
WO2019168999A1 (en) 2019-09-06
JP7348906B2 (ja) 2023-09-21
AR114417A1 (es) 2020-09-02
MX2023001527A (es) 2023-03-06
SG11202008230PA (en) 2020-09-29
EP3759075A1 (en) 2021-01-06
AU2019229256A1 (en) 2020-09-17
CN112041301A (zh) 2020-12-04
US20230039846A1 (en) 2023-02-09
CA3092143A1 (en) 2019-09-06
JP2021515010A (ja) 2021-06-17
US20190263802A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
MX2023001527A (es) Compuestos con actividad inductora de ferroptosis y metodos de uso de estos.
WO2020121310A3 (en) Method of treating cancer with a cancer therapy in combination with another therapeutic agent
MX2021010173A (es) Compuestos con actividad inductora de ferroptosis y métodos de uso.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
MX2021004821A (es) Uso de antagonistas contra muerte programada 1 (pd-1) y ligando de muerte programada 1 (pd-l1) en combinacion con radioterapia.
MX2022008868A (es) Tratamiento del cancer con tg02.
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
MX2017005929A (es) Terapia de combinacion con agonistas de unión ox40 e inhibidores de tigit.
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2021000847A (es) Procedimientos para el tratamiento del cancer con el inhibidor de pi3k, gdc 0077.
MX2020001727A (es) Terapia de combinacion.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
MX2018005233A (es) Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer.
MX2019013862A (es) Terapia de combinacion.
MX2019008233A (es) Nanoconjugados de doxorrubicina y oro dirigidos para terapia tumoral.
WO2021041539A3 (en) Pyrido-indole analogues as gpx4 inhibitors
MX2020006224A (es) Metodos y terapia combinada para el tratamiento del cancer.
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
PH12018502381A1 (en) Dihydrotestosterone and dihydrotestosterone derivatives and promoters in the treatment of cancer
MX2019003751A (es) Proteina terapeutica.
BR112019004791A2 (pt) tratamento de esclerose múltipla com chs-131
MX2018010223A (es) Terapia combinada para tratamiento de cancer de ovario.
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
EA202193276A1 (ru) Способы лечения холангиокарциномы
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.